Publication | Closed Access

A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma

Dose-escalation StudyMedicineMelanomaImmunologyImmune Checkpoint InhibitorMolecular OncologyPhase 1ACancer TreatmentOncologyRadiation OncologyAdvanced Nras-mutant MelanomaTumor Biology